Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Core Viewpoint - Palisade Bio, Inc. has announced a public offering of 171,440,559 shares of its common stock at a price of $0.70 per share, aiming to raise approximately $120 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 25,714,285 shares at the public offering price [2]. - The expected closing date for the offering is around October 2, 2025, pending customary closing conditions [3]. - A registration statement related to the offering was declared effective by the SEC on September 30, 2025, with an additional statement filed on October 1, 2025 [4]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]. - The company aims to transform the treatment landscape through a targeted approach with its therapeutics [6].